Photosensitizing Medications and Skin Cancer: A Comprehensive Review.
Elisabeth A GeorgeNavya BaranwalJae Hee KangAbrar A QureshiAaron M DruckerEunyoung ChoPublished in: Cancers (2021)
(1) The incidence of skin cancer is increasing in the United States (US) despite scientific advances in our understanding of skin cancer risk factors and treatments. In vitro and in vivo studies have provided evidence that suggests that certain photosensitizing medications (PSMs) increase skin cancer risk. This review summarizes current epidemiological evidence on the association between common PSMs and skin cancer. (2) A comprehensive literature search was conducted to identify meta-analyses, observational studies and clinical trials that report on skin cancer events in PSM users. The associated risks of keratinocyte carcinoma (squamous cell carcinoma and basal cell carcinoma) and melanoma are summarized, for each PSM. (3) There are extensive reports on antihypertensives and statins relative to other PSMs, with positive and null findings, respectively. Fewer studies have explored amiodarone, metformin, antimicrobials and vemurafenib. No studies report on the individual skin cancer risks in glyburide, naproxen, piroxicam, chlorpromazine, thioridazine and nalidixic acid users. (4) The research gaps in understanding the relationship between PSMs and skin cancer outlined in this review should be prioritized because the US population is aging. Thus the number of patients prescribed PSMs is likely to continue to rise.
Keyphrases
- skin cancer
- risk factors
- squamous cell carcinoma
- clinical trial
- end stage renal disease
- systematic review
- cardiovascular disease
- case control
- chronic kidney disease
- peritoneal dialysis
- type diabetes
- randomized controlled trial
- ejection fraction
- newly diagnosed
- prognostic factors
- emergency department
- climate change
- radiation therapy
- lymph node metastasis
- patient reported